Resources for Food and Drug Administration (FDA)

Thanks for Nothing, FDA

www.fool.com

Almost exactly a year after Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP) released data from their Enhance trial showing that their cholesterol-fighting drug, Vytorin, wasn't able to lower the amount of plaque in a neck artery more than Zocor did, the Food and Drug Administration says there's still enough evidence that Vytorin works to warrant keeping patients on the drug.Thanks for the vote of confidence, FDA, but I think the damage has already been done.Year-over-year sales of the duo's cholesterol-fighting drugs, Zetia and Vytorin (the latter being a comination of Zetia and Zocor), fell by 15% in the third quarter of last year, as patients migrated to Pfizer's (NYSE: PFE) Lipitor, AstraZeneca's (NYSE: AZN) Crestor, or generic versions of statins such as Merck's Zocor or Bristol-Myers Squibb's (NYSE: BMY) Pravachol.

View the Resource

Share or bookmarklet this web page at: